Work

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial

Year: 2019

Type: article

Source: Hematological Oncology

DOI: 10.1002/hon.33_2629

Authors: S.M. Horwitz, F.M. Foss, P. Porcu, A. Moskowitz, N. Mehta‐Shah, E. Jacobsen, M.S. Khodadoust, Y.H. Kim, D. Weinstock, S. Lustgarten, M. Baglio, H. Youssoufian, J. Brammer

Institutions: Memorial Sloan Kettering Cancer Center, Yale Cancer Center, Thomas Jefferson University, Sidney Kimmel Cancer Center, Washington University in St. Louis, Stanford Cancer Institute, Stanford University, Dana-Farber Cancer Institute, Verastem (United States), The Ohio State University

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2952488801

FWCI:

Cites:

Cited by: 2

Related to: 10